Strategic partnerships Array BioPharma collaborates with multiple large pharma companies (AstraZeneca, Roche, Genentech, Loxo Oncology, Cascadian Therapeutics) and has several partnered drugs, indicating ongoing collaboration opportunities and a pipeline that may benefit from expanded licensing, co-development, or regional commercialization deals.

Expansion potential Recent headcount growth and a 22-acre expansion suggest capacity to scale research, development, and manufacturing operations, presenting sales opportunities for CRO, clinical support, lab equipment, or contract manufacturing services to support accelerated development timelines.

Clinical leadership shifts Frequent leadership changes in the chief medical officer role and notable past leaders with oncology success indicate a company open to advisory, clinical development services, patient-centric trial design input, and strategic partnerships to de-risk late-stage programs.

Regulatory & approvals Track record of regulatory success for Braftovi and Mektovi, plus ongoing registration studies for several drugs, implies opportunities to offer regulatory consulting, pharmacovigilance, or post-approval surveillance solutions to support near-term commercialization.

Financial footing Moderate revenue range with substantial funding runway positions Array for continued R&D investments; sales opportunities exist in high-value enabling technologies, analytics, and diagnostics that align with its oncology focus and pipeline.